| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | rituximab (MabThera®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 408 |
| Indication | Treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/06/2019 |
| NICE guidance | TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |